Search results
Results from the WOW.Com Content Network
This work includes material that may be protected as a trademark in some jurisdictions. If you want to use it, you have to ensure that you have the legal right to do so and that you do not infringe any trademark rights. See our general disclaimer. This tag does not indicate the copyright status of the attached work.
This work includes material that may be protected as a trademark in some jurisdictions. If you want to use it, you have to ensure that you have the legal right to do so and that you do not infringe any trademark rights. See our general disclaimer. This tag does not indicate the copyright status of the attached work.
English: The YouTube logo introduced on December 19, 2013 Suomi: YouTuben logo vuosina 2013–2015 Tagalog: Ang logo ng YouTube na unang ipinakita noong ika- 19 ng Disyembre, 2013
Sorry Corkythehornetfan,you never revert this anymore! 04:27, 9 April 2016: 999 × 417 (10 KB) Corkythehornetfan: Revert -- I've used an OFFICIAL SOURCE for the color, and yet the person who keeps reverting can't respond on their page. THIS IS THE OFFICIAL COLOR FROM YOUTUBE'S BRAND GUIDE. LEAVE IT, PLEASE! 04:24, 9 April 2016: 999 × 417 (10 KB)
Deutsch: YouTube-Markenzeichen seit 2017, mit einer Schriftart welche den Schriftarten „Trade Gothic Bold Condensed“ und „Impact“ ähnelt. English: YouTube logo introduced in 2017, using YouTube Logo Sans, a font face that resembles "Trade Gothic Bold Condensed" and the well-known "Impact" font.
SVG update: Shadow of the “[Tube]” is not a gradient of the same object anymore but a separate transparent object. Edited using InkScape. 21:20, 10 October 2019: 1,105 × 440 (15 KB) Handroid7: Removing white “You” text leftover from original in the background. 21:16, 10 October 2019: 1,105 × 440 (17 KB) Handroid7
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.